RT-PCR Kits Market Size, Share, and Industry Analysis By Type (Quantitative and Digital), By Application (Diagnostics {Infectious Diseases, Oncology, Genetic Testing, and Others}, Research & Development, and Others), By End-user (Biotechnology & Pharmaceutical Companies, Hospitals & Clinics Based Laboratories, Standalone Laboratories, and Others), and Regional Forecast, 2025-2032

The global RT-PCR kits market is projected to experience substantial growth due to the increasing number of disease incidences. The RT-PCR kits or the reverse transcription PCR kits refer to the kits that convert RNA to complementary DNA (cDNA) and enable for PCR amplification. The market includes the reagents used for the cDNA conversion from RNA and PCR amplification. The rising awareness about diagnostics and the demand for nucleic acid amplification tests are expected to increase the adoption of RT-PCR kits across the globe. These kits are used in the drug discovery, target identification, and gene specific diagnosis of cancer and other diseases.

• In 2022, World Cancer Research Fund International estimated that there were 19.9 million new cancer cases worldwide, which increases the demand for cancer diagnosis and demand for RT-PCR kits.

RT-PCR Kits Market Driver

Increasing Demand for Rapid Detection to Boost the Market

The increasing need for rapid and custom diagnostic tests is a key driver propelling the growth of the RT-PCR kits market. These RT-PCR tests allow for the swift and precise identification of a range of infectious and chronic diseases. Additionally, the rising strategic initiatives by key players, such as collaborations and acquisitions with the other emerging players to offer advanced kits and devices in digital PCR technologies, will further enhance the market growth over the forecast period. 

• In December 2023, HiMedia Laboratories launched their one step RT-PCR kit for the detection of the COVID-19-JN1 variant. Such strategic collaborations help expand the market growth through the increasing new product launches.

Download Free sample to learn more about this report.

RT-PCR Kits Market Restraint

Issues of Low Sensitivity and False Detection May Limit Market Growth

Low sensitivity and false detections are the two major limitations of these kits that can hinder market growth. The kits ability to synthesize quality complement DNA determines the outcome of the test. Additionally, the smaller number of target base pairs can lead to inaccuracy in the detection, which can limit the market growth.

RT-PCR Kits Market Opportunity

Rising Focus of Industry Players on Partnerships to Create Growth Opportunities

Major market players are focusing on collaborations and partnerships with other market players to bolster their new product launches and strengthen their distribution networks. Such an increase in the number of strategic collaborations and partnerships is expected to offer lucrative opportunities for market growth during the forecast period.

• For instance, in January 2022, QIAGEN collaborated with German life-sciences start-up Actome GmbH. This collaboration expands the company’s distribution ability.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries, 2023
• Overview: Technological Advancements in the RT-PCR Kits
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market 

Segmentation

Analysis by Type

Based on type, the market is categorized into quantitative and digital.

The quantitative segment held a significant revenue in the market. The extensive availability of these kits and their cost-effectiveness are the factors expected to drive segmental growth. In addition, the new product launches for various applications and the expansion of the distribution networks are expected to drive the segment growth.

• In March 2022, Stilla announced its partnership with 12 distributors across the EMEA region. With this partnership, the company expanded its presence in the EMEA region.

Analysis by Application

In terms of application, the market is subdivided into diagnostics {infectious diseases, oncology, genetic testing, and others}, research & development, and others.

The diagnostics segment accounted for a significant share of the RT-PCR kits market. The diagnostics segment can be further sub-segmented into infectious diseases, oncology, genetic testing, and others. The increasing number of product launches and rising government initiatives for the expedited approval of testing kits are the major factors contributing to the segment growth.

• For instance, in November 2021, Genes2Me launched an extraction-free RT-PCR kit for COVID-19 detection that gives results in 40 minutes, which can increase the market growth.

Analysis by End-user

Based on end-user, the market is categorized into biotechnology & pharmaceutical companies, hospitals & clinics based laboratories, standalone laboratories, and others.

The standalone laboratories segment accounted for a significant share of the market. The segment is expected to grow at a higher CAGR as the incidence of infectious diseases increases, which requires nucleic acid amplification for rapid detection. As these standalone laboratories process most of the samples, the segmental growth is expected in the near future. Additionally, investments in the new lab construction and adoption of the one step kit can increase their diagnostic capabilities and the market is expected to grow over the projected years.

• For instance, in April 2022, Mayo Clinic invested in a major laboratory expansion project in Rochester. The expansion includes an USD 49.0 million investment in the laboratory. The construction for the project has already started and will continue through 2025.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a significant share of the market in 2023. The growth of the market in the region is attributed to the extensive presence of key players and the rising introduction of advanced kits. Moreover, the increasing adoption of advanced kits for diagnostics in the region is also expected to propel the regional growth during the forecast period.

• For instance, in November 2022, Thermo Fisher Scientific Inc., launched the digital PCR liquid-biopsy RT-PCR kits for academic and clinical research. Such product launches increase the penetration of advanced kits, which may further increase the market growth.

Europe is the second-largest market based on the demand for RT-PCR Kits. The demand is expected to increase as the incidence of chronic and infectious diseases. Additionally, the presence of well-established R&D centers in the region is expected to utilize advanced RT-Kits for drug discovery and development.

• For instance, according to the European Journal of Cancer, 2.7 million new cancer cases were diagnosed across Europe in 2020. Such a high rate of cancer diagnostics can increase the RT-PCR kits for diagnostics.

The Asia Pacific region is poised for significant growth in the diagnostic market over the coming years, driven by several key factors. One of the primary contributors to this growth is the escalating number of infections across various diseases, which has heightened the demand for timely and accurate diagnostic solutions. In addition to the increasing disease burden, there is a growing awareness surrounding the importance of early diagnosis and the role it plays in improving patient outcomes. These factors can significantly increase the demand of RT-PCR kits for diagnostics.

Key Players Covered

The global RT-PCR kits market is partially fragmented with major and medium sized players and the report  includes the profiles of the following key players:

• QIAGEN (Germany)
• Merck KGaA (Germany)
• Takara Bio Inc. (Japan)
• Thermo Fisher Scientific Inc. (U.S.)
• Promega Corporation (U.S.)
• altona Diagnostics GmbH (Germany)
• Zymo Research Corporation (U.S.)

Key Industry Developments

• In January 2022, JN Medsys launched a RT-PCR test kit that specifically detects the COVID-19 Omicron variant with high accuracy. With the launch of this product, the company expanded its product portfolio for COVID-19 test kits.
• In July 2022, QIAGEN added 13 new biopharma kits and assays including RT-PCR kits in its digital PCR portfolio. The new products are launched to quantify Adeno-associated virus (AAV) viral titer and residual host cell DNA in cell and gene therapy.
• In June 2020, PreciGenome LLC received Emergency Use Authorization (EUA) for FastPlex Triplex SARS-CoV-2 detection kit (RT-Digital PCR).